How AI is shifting life sciences from blockbuster drugs to continuous R&D

For decades, life sciences innovation has followed a familiar model: Identify a promising molecule, advance it through a linear pipeline and bring it to market. This approach has delivered remarkable blockbuster drug breakthroughs – from statins that have reduced cardiovascular deaths to curative treatments for hepatitis C.

But in today’s world, which is increasingly shaped by continuous data generation, artificial intelligence- (AI-) driven discovery and rising expectations around long-term patient outcomes, this model is no longer sufficient. A new paradigm is emerging.

The life sciences industry is entering a period of profound structural change. AI and other deep technologies are creating unprecedented opportunities to tackle some of the world’s most complex medical challenges – from cancer and neurodegenerative disorders to rare diseases that still lack complete understanding or effective cures.

But realizing this potential requires more than incremental innovation. It demands a fundamental shift in how the industry is organized, operates and collaborates within healthcare ecosystems.

Rather than progressing as a series of discrete efforts, life sciences research and development (R&D) is beginning to resemble a continuously running system. This shift is reshaping competitive advantage, changing how and where value is created and opening new strategic options for leaders, according to a new World Economic Forum report in collaboration with BCG, called Strategic Choices in the Age of AI: Shaping the Future of Life Sciences.

AI is embedded across the process creating a self-learning loop. In this model, the idea of a “project” fades. R&D becomes cyclical – design, test, learn and iterate. Over time, this produces a system capable of continuous improvement. The implication is that value no longer comes from a single breakthrough, but from the ability to consistently generate results.

And as AI lowers the barriers to discovery, more actors can generate hypotheses and design molecules. But this does not make innovation easier, it shifts the bottleneck. Turning ideas into therapies that are validated, approved and deployed in real-world systems remains complex. It requires experimental validation, clinical development, regulatory approval and manufacturing scale.

In a system-driven model, data becomes the foundation of value where quality matters more than volume. Data must be clean, consistent and traceable. Systems must capture both successes and failures, turning every experiment into a lesson learned.

At the same time, expectations around evidence are changing. It is no longer enough to show that a drug works, companies must explain how results were achieved – how models evolved, where data originated and whether the process is auditable.

The integrity of the evidence becomes as important as the result itself. Data and especially the ability to turn the data into evidence is gaining strategic importance. And as R&D becomes adaptive, regulatory models must also evolve. Traditional approaches rely on discrete approvals, but this is insufficient for systems that continuously learn and update.

Regulation is likely to shift toward ongoing oversight focused on traceability, auditability and control. Governance must be embedded into the system using data standards, version control and accountability structures that are built-in from the start.

The definition of value in life sciences is also shifting. Historically, value was tied to clinical performance at a point in time. Increasingly, it is defined by long-term outcomes – adherence, reduced hospitalizations and improved quality of life.

This reflects broader changes. Patients are accessing information earlier, often forming views through digital platforms such as online health resources, social media or emerging AI chatbots before entering care. At the same time, ageing populations and chronic disease are pushing healthcare systems toward long-term management.

All of this contributes to the fact that value is now created through continuous engagement across the patient lifecycle.

The life sciences R&D ecosystem is shifting from a linear process to a layered system.

At the base are infrastructure capabilities such as automated laboratories, data systems and computational platforms. Above this sits problem definition and strategy. At the top is execution that advances therapies through trials, approval and real-world use.

At the same time, innovation is becoming more decentralized, while validation and scaling are becoming more centralized. More people can generate ideas, but only a few can turn them into globally accepted outcomes. This creates an “open front-end, centralized back-end” model in which ideas can come from anywhere, but scaling requires concentrated capabilities.

As a result, competition is shifting from products to systems. The key question is no longer who has the best molecule, but who can operate the most effective system by integrating data, experimentation, validation and governance.

This shift is also reshaping the global landscape. China’s life sciences ecosystem has rapidly evolved from a low-cost manufacturing base into a global innovation powerhouse. The average upfront value of licensing deals between Western biopharma and Chinese companies has risen by more than 230% in recent years, signalling growing confidence in the quality, speed and sophistication of Chinese R&D.

Chinese companies have clear strengths in engineering and large-scale execution, advantages that reinforce their position in the infrastructure layer. However, long-term global leadership will depend on whether they can build equally strong capabilities in the higher layers by defining the right problems and translating innovations across regions and regulatory systems.

The real challenge in life sciences isn’t technology, it's transformation. A risk-averse industry long organized around products and departments is too slow and fragmented for continuous, system-driven R&D. And while new tools can be deployed quickly, reshaping governance, accountability and culture takes far longer.

At the same time, companies must rethink their role because success will no longer come from selling products, but from managing the patient lifecycle. This means delivering ongoing support, improving long-term outcomes and providing additional services such as education, risk warnings and follow-ups.

This broader shift redefines innovation itself: R&D becomes continuous, value moves from blockbuster products to outcomes and competition shifts to integrated systems. Ultimately, the winners won’t be those with the most ideas, but those that can consistently turn ideas into scalable, trusted outcomes.